RxDoctor Payments Data

Cindy Lam, PA

Physician Assistant · Concord, MANPI 1881267011

Payments from drug & device makers

$2,001in general payments, 2019–2025

Across 64 payments — averaging $31.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$818
  • AstraZeneca$222
  • Daiichi Sankyo Inc.$213
  • Incyte Corporation$170
  • Mirati Therapeutics, Inc.$125
  • Johnson & Johnson$125
  • plus $328 from 7 others

What the payments were for

  • Food & beverage$1,73287%
  • Education$26913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,001 in reported general payments places this provider in the 90th percentile of 3,507 physician assistant providers in Massachusetts.

See all physician assistant providers in Massachusetts

Medicare billing

Part B allowed, 2024
$55,685
Medicare patients
206
Services billed
1,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide62$1,112,228
Lenalidomide66$807,392
TasignaNilotinib Hcl32$460,107
ImbruvicaIbrutinib26$423,625
PromactaEltrombopag Olamine15$228,249
CalquenceAcalabrutinib Maleate12$185,175
KisqaliRibociclib Succinate14$178,521
XtandiEnzalutamide12$169,822
ReblozylLuspatercept-Aamt13$141,567
XareltoRivaroxaban28$35,420
EliquisApixaban25$34,353
FaslodexFulvestrant13$23,593
Letrozole120$2,453
Anastrozole149$2,365
Exemestane11$2,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$57$1,112,22862 claims
NovartisTasigna, Promacta, Kisqali$818$866,87761 claims
AstraZenecaCalquence, Faslodex$222$208,76825 claims
Johnson & JohnsonXarelto$125$35,42028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,507 physician assistant providers in Massachusetts.

Other physician assistant in Concord

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →